Financial incentive increases CPAP acceptance in patients from low socioeconomic background

Ariel Tarasiuk, Gally Reznor, Sari Greenberg-Dotan, Haim Reuveni, Ariel Tarasiuk, Gally Reznor, Sari Greenberg-Dotan, Haim Reuveni

Abstract

Objective: We explored whether financial incentives have a role in patients' decisions to accept (purchase) a continuous positive airway pressure (CPAP) device in a healthcare system that requires cost sharing.

Design: Longitudinal interventional study.

Patients: The group receiving financial incentive (n = 137, 50.8±10.6 years, apnea/hypopnea index (AHI) 38.7±19.9 events/hr) and the control group (n = 121, 50.9±10.3 years, AHI 39.9±22) underwent attendant titration and a two-week adaptation to CPAP. Patients in the control group had a co-payment of $330-660; the financial incentive group paid a subsidized price of $55.

Results: CPAP acceptance was 43% greater (p = 0.02) in the financial incentive group. CPAP acceptance among the low socioeconomic strata (n = 113) (adjusting for age, gender, BMI, tobacco smoking) was enhanced by financial incentive (OR, 95% CI) (3.43, 1.09-10.85), age (1.1, 1.03-1.17), AHI (>30 vs. <30) (4.87, 1.56-15.2), and by family/friends who had positive experience with CPAP (4.29, 1.05-17.51). Among average/high-income patients (n = 145) CPAP acceptance was affected by AHI (>30 vs. <30) (3.16, 1.14-8.75), living with a partner (8.82, 1.03-75.8) but not by the financial incentive. At one-year follow-up CPAP adherence was similar in the financial incentive and control groups, 35% and 39%, respectively (p = 0.82). Adherence rate was sensitive to education (+yr) (1.28, 1.06-1.55) and AHI (>30 vs. <30) (5.25, 1.34-18.5).

Conclusions: Minimizing cost sharing reduces a barrier for CPAP acceptance among low socioeconomic status patients. Thus, financial incentive should be applied as a policy to encourage CPAP treatment, especially among low socioeconomic strata patients.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow chart showing stages of…
Figure 1. Flow chart showing stages of the diagnostic and therapeutic process and number of patients at each stage.

References

    1. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thor Soc. 2008;5:136–43.
    1. Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D, et al. American Academy of Sleep Medicine. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006;29:375–80.
    1. Gay P, Weaver T, Loube D, Iber C. Positive Airway Pressure Task Force; Standards of Practice Committee; American Academy of Sleep Medicine. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep. 2006;29:381–401.
    1. Weaver TE, Maislin G, Dinges DF, Bloxham T, George CF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007;30:711–9.
    1. McArdle N, Kingshott R, Engleman HM, Mackay TW, Douglas NJ. Partners of patients with sleep apnoea/hypopnoea syndrome: effect of CPAP treatment on sleep quality and quality of life. Thorax. 2001;56:513–8.
    1. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lance. 2005;365:1046–53.
    1. McDaid C, Duree KH, Griffin SC, Weatherly HL, Stradling JR, et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. Int J Technol Assess Health Care. 2009;25:26–34.
    1. McDaid C, Griffin S, Weatherly H, Durée K, van der Burgt M, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technol Assess 13:iii-iv, xi-v, 1–119, 2009;143–274
    1. Guest JF, Helter MT, Morga A, Stradling JR. Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnoea/hypopnoea syndrome in the UK. Thorax. 2008;63:860–5.
    1. Ayas NT, FitzGerald JM, Fleetham JA, White DP, Schulzer M, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med. 2006;166:977–84.
    1. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med. 2004;169:348–53.
    1. Martínez-García MA, Soler-Cataluña JJ, Ejarque-Martínez L, Soriano Y, Román-Sánchez P, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med. 2009;180:36–41.
    1. Marti S, Sampol G, Muñoz X, Torres F, Roca A, et al. Mortality in severe sleep apnoea/hypopnoea syndrome patients: impact of treatment. Eur Respir J. 2002;20:1511–8.
    1. Albarrak M, Banno K, Sabbagh AA, Delaive K, Walld R, et al. Utilization of healthcare resources in obstructive sleep apnea syndrome: a 5-year follow-up study in men using CPAP. Sleep. 2005;28:1306–11.
    1. Brin YS, Reuveni H, Greenberg-Dotan S, Tal, A, Tarasiuk A. Determinants affecting initiation of continuous positive airway pressure treatment. Isr Med Assoc J. 2005;7:13–8.
    1. Simon-Tuval T, Reuveni H, Greenberg-Dotan S, Oksenberg A, Tal A, et al. Low socioeconomic status is a risk factor for CPAP acceptance among adult OSAS patients requiring treatment. Sleep. 2009;32:545–52.
    1. Olsen S, Smith S, Oei T, Douglas J. Health belief model predicts adherence to CPAP before experience with CPAP. Eur Respir J. 2008;32:710–7.
    1. Reuveni H, Tarasiuk A, Wainstock T, Ziv A, Elchayani A, et al. Awareness level to obstructive sleep apnea syndrome during routine unstructured interviews of a standardized patient by primary care physicians. Sleep. 2004;27:1518–25.
    1. Lettieri CJ, Shah AA, Holley AB, Kelly WF, Chang AS, et al. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009;15:696–702.
    1. Hoy CJ, Vennelle M, Kingshott RN, Engleman HM, Douglas NJ. Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? Am J Respir Crit Care Med. 1999;159:1096–100.
    1. Popescu G, Latham M, Allgar V, Elliott MW. Continuous positive airway pressure for sleep apnea/hypopnoea syndrome: usefulness of a 2-week trial to identify factors associated with long term use. Thorax. 2001;56:727–33.
    1. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5:173–8.
    1. Stepnowsky CJ, Bardwell WA, Moore PJ, Ancoli-Israel S, Dimsdale JE. Psychologic correlates of compliance with continuous positive airway pressure. Sleep. 2002;25:758–62.
    1. Aloia MS, Arnedt JT, Stepnowsky C, Hecht J, Borrelli B. Predicting treatment adherence in obstructive sleep apnea using principles of behavior change. J Clin Sleep Med. 2005;1:346–53.
    1. Mackenbach JP, Stirbu I, Roskam AJ, Schaap MM, Menvielle G, et al. European Union Working Group on Socioeconomic Inequalities in Health. Socioeconomic inequalities in health in 22 European countries. N Engl J Med . 2008;358:2468–81.
    1. Tarasiuk A, Greenberg-Dotan S, Simon T, Tal A, Oksenberg A, et al. Low socioeconomic status is a risk factor for cardiovascular disease among adult OSAS patients requiring treatment. Chest. 2006;130:766–73.
    1. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359–67.
    1. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61–9.
    1. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626–34.
    1. Reuveni H, Sheizaf B, Elhayany A, Sherf M, Limoni Y, et al. The effect of drug co-payment policy on the purchase of prescription drugs for children with infections in the community. Health Policy. 2002;6:1–13.
    1. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344–50.
    1. Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood) 2007;26:186–94.
    1. Giuffrida A, Torgerson DJ. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. 1997;315:703–7.
    1. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861–7.
    1. Fendrick AM. Value-based insurance design for diabetes mellitus: approaches to optimal pharmacoeconomic implementation. Am J Manag Care. 2010;16:S314–22.
    1. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11:S170–6.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540–54.
    1. Kump K, Whalen C, Tishler PV, Browner I, Ferrette V, et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med. 1994;150:735–41.
    1. Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, et al. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis. 1993;147:887–95.
    1. Smith S, Lang C, Sullivan K, Warren J. Two new tools for assessing patients′ knowledge and beliefs about obstructive sleep apnea and continuous positive airway pressure therapy. Sleep Med. 2004;5:359–67.
    1. Reuveni H, Greenberg-Dotan S, Simon-Tuval T, Oksenberg A, Tarasiuk A. Young Adult Males with OSA Consume High Health Care Resources due to Nonspecific Co-Morbidity. Eur Respir J. 2008;31:273–9.
    1. Tarasiuk A, Greenberg-Dotan S, Simon T, Tal A, Oksenberg A, et al. Elderly with Obstructive Sleep Apnea Consume High Health Care Resources due to elevated cardiovascular morbidity. J Am Geriatr Soc. 2008;56:247–54.
    1. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283:1829–36.
    1. DiMatteo MR. Variations in patients′ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200–9.
    1. Greenberg H, Fleischman J, Gouda HE, De La Cruz AE, Lopez R, et al. Disparities in obstructive sleep apnea and its management between a minority-serving institution and a voluntary hospital. Sleep Breath. 2004;8:185–92.
    1. Platt AB, Field SH, Asch DA, Chen Z, Patel NP, et al. Neighborhood of residence is associated with daily adherence to CPAP therapy. Sleep. 2009;32:799–806.
    1. Sutherland K, Christianson JB, Leatherman S. Impact of targeted financial incentives on personal health behavior: a review of literature. Med Care Res Rev Suppl. 2008;65:36S–78S.
    1. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood) 2010;29:2002–8.
    1. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) 2008;27:103–12.
    1. Bandura A. Englewood Cliffs, NJ: Prentice-Hall; 1986. Social Foundations of thought and action: a social cognitive theory.
    1. Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood) 2010;29:530–6.
    1. Braithwaite RS, Omokaro C, Justice AC, Nucifora K, Roberts MS. Can broader diffusion of value-based insurance design increase benefits from US health care without increasing costs? Evidence from a computer simulation model. PLoS Med. 2010;7:e1000234.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi